One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The original GlobalRPh and 2019 handbook eGFR 60 restriction is historical. Use the indication-specific FARXIGA label addition below; the glycemic threshold is not the HF/CKD initiation threshold.
The older mirror and June 2026 label retain different thresholds for glycemic and other adult indications. The official surgery paragraph no longer limits its wording to major surgery.
What to reconcile: Use the newer source wording within its scope; a continuation statement below 25 is not a general initiation/dialysis rule.
Open this note and its source referencesUse the indication-specific threshold and distinguish initiation from continuation.
Dialysis evidence: No dialysis regimen established in selected content
For glycemic control, use is not recommended below eGFR 45 mL/min/1.73 m2. For other adult indications, the recommended dose is 10 mg daily; do not initiate below 25. Patients already receiving it whose eGFR declines below 25 may continue 10 mg daily for the specified cardiorenal risk reduction. Renal function and volume status require assessment; correct depletion before starting. Withhold at least 3 days, if possible, before surgery or prolonged-fasting procedures; restart when clinically stable and eating. Trials did not enroll patients initially below eGFR 25 or on dialysis; trial continuation after decline or dialysis initiation is not universal permission to start in dialysis. Glycemic and cardiorenal indications must remain separate.
RDM61-official-general-dapagliflozin-44ff2ec02c-C1 · Source locator: 2.1-2.4 and 8.6
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=general-dapagliflozin&s1=RDM61-official-general-dapagliflozin-44ff2ec02c&h1=ad07b321e263a8259ea696742312135ada577f7a9378e1aef6931c3cdc849a79